Migraine is currently understood as a complex, variable disorder of nervous system function, rather than simply a vascular headache. For most patients, it is a lifelong condition with variable expression over time. Patients with migraine often experience significant disability. In recent years, new pharmacologic strategies for migraine have emerged that address some of the challenges associated with conventional therapies. These include agents that target calcitonin gene-related peptide (CGRP), a neuropeptide central to migraine pathophysiology that has been observed to increase during a migraine. This program addresses the pathophysiology of migraine and the role of the CGRP pathway; diagnosis and treatment of acute migraine; treatments to prevent migraine, including anti-CGRP therapies; and how to integrate CGRP inhibitors into clinical practice.